# Regorafenib Combined With Fulvestrant in Recurrent Low-Grade Serous Ovarian Cancer

> **NCT05113368** · PHASE2 · RECRUITING · sponsor: **Sarah K. Lynam MD** · enrollment: 31 (estimated)

## Conditions studied

- Ovarian Cancer
- Serous Ovarian Cancer

## Interventions

- **DRUG:** Regorafenib
- **DRUG:** Fulvestrant

## Key facts

- **NCT ID:** NCT05113368
- **Lead sponsor:** Sarah K. Lynam MD
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-06-28
- **Primary completion:** 2026-09
- **Final completion:** 2027-02
- **Target enrollment:** 31 (ESTIMATED)
- **Last updated:** 2025-08-21

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05113368

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05113368, "Regorafenib Combined With Fulvestrant in Recurrent Low-Grade Serous Ovarian Cancer". Retrieved via AI Analytics 2026-07-05 from https://api.ai-analytics.org/clinical/NCT05113368. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*